Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

Cancer Network Information System Cymru (CaNISC) includes multidisciplinary team diagnosis, proposed treatments, and a system-generated summary of the patient’s cancer record.

The core system used across Wales has been CaNISC. This system provided the cancer patient record of treatment, the patient administration system for Velindre Cancer Centre, and was the primary source of cancer data for waiting times, clinical audit, and cancer registration.

Velindre Cancer Centre successfully migrated from CaNISC onto the new Cancer Informatics System (CIS) in November 2022.

Why is CaNISC being replaced?

Whilst CaNISC allowed multiple organisations to record the diagnosis, treatment and follow-up care information for a patient, it could only be accessed by approximately 2000 authorised health care professionals. Patients receive care in many settings outside of the cancer centres and their cancer care clinical information was often not available to other health professionals treating patients for other health related issues in other care settings.

CaNISC approached the end of its viable service as it could no longer be updated to keep pace with changing clinical practices and processes. The 2018 Cancer Delivery Plan for Wales included an action to explore the replacement of CaNISC, resulting in a business case being submitted to the Welsh Government to develop a new Cancer Information System for Wales.

Welsh Government agreed a £6.5 million investment from the Digital Priorities Investment Fund in 2019 spanning three financial years, working with Digital Health and Care Wales (DHCW), health boards and trusts to deliver the Cancer Informatics Programme.

A Data Explained report on CNIS can be found here: https://adrwales.org/wp-content/uploads/2025/02/Data_Explained_CNIS.pdf

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

The share of the population with overweight in the United States was forecast to continuously increase between 2024 and 2029 by in total 1.6 percentage points. After the fifteenth consecutive increasing year, the overweight population share is estimated to reach 77.43 percent and therefore a new peak in 2029. Notably, the share of the population with overweight of was continuously increasing over the past years.Overweight is defined as a body mass index (BMI) of more than 25.The shown data are an excerpt of Statista's Key Market Indicators (KMI). The KMI are a collection of primary and secondary indicators on the macro-economic, demographic and technological environment in up to 150 countries and regions worldwide. All indicators are sourced from international and national statistical offices, trade associations and the trade press and they are processed to generate comparable data sets (see supplementary notes under details for more information).Find more key insights for the share of the population with overweight in countries like Canada and Mexico.

BackgroundThe optimal second-line systemic treatment for metastatic colorectal cancer (mCRC) is inconclusive.MethodsWe searched PubMed, Web of Science, EMBASE, and Cochrane Library for RCTs comparing second-line systemic treatments for mCRC from the inception of each database up to February 3, 2024. Markov Chain Monte Carlo (MCMC) technique was used in this network meta-analysis (NMA) to generate the direct and indirect comparison results among multiple treatments in progression-free survival (PFS), overall response rate (ORR), overall survival (OS), complete response (CR), partial response (PR), grade 3 and above adverse events (Grade ≥ 3AE), and any adverse events (Any AE). The surface under the cumulative ranking curve (SUCRA) was adopted to evaluate the probability of each treatment being the optimum intervention. Subgroup analyses were performed based on the RAS gene status.ResultsA total of 47 randomized controlled trials were included, involving 16,925 patients and 44 second-line systemic treatments. In improving OS, FOLFOX + Bevacizumab + Erlotinib exhibited significant superiority (SUCRA:92.7%). In improving PFS, Irinotecan + CMAB009 (SUCRA:86.4%) had advantages over other treatments. FOLFIRI + Trebananib (SUCRA:88.1%) had a significant advantage in improving ORR. Among multiple second-line treatments, the SUCRA values of FOLFOX + Bevacizumab in PFS, OS, ORR, and PR were 83.4%, 74.0%, 81.1%, and 86.1%, respectively, and the safety was not significantly different from other interventions. Subgroup analyses showed that FOLFIRI + Bevacizumab + panitumumab ranked among the top in survival outcomes in the RAS-mutant population (OS SUCRA: 87.9%; PFS SUCRA: 70.2%); whereas in the RAS-wild-type population, FOLFIRI + Bevacizumab significantly improved survival outcomes (OS SUCRA: 73.2%; PFS SUCRA: 65.1%).ConclusionFor most people, FOLFOX + Bevacizumab may be the best second-line systemic treatment regimen for mCRC. For RAS-mutant populations, FOLFIRI + Bevacizumab + Panitumumab is recommended. However, the therapeutic effect may be affected by the patient’s physiological state, and clinicians should apply it based on actual conditions.